Novadiol — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Novadiol is a Kansas City-based biopharma company founded in 2012, targeting the large and growing chronic kidney disease market. Its core asset is Dendocrin™, a repurposed drug with a known safety profile, aimed at treating secondary hyperparathyroidism (SHPT) in CKD patients via a 505(b)(2) NDA. The company emphasizes strong worldwide patent protection, low development risk, and an experienced management team as it seeks capital and partnerships to advance its pipeline.

NephrologyChronic Kidney Disease

Technology Platform

Method-of-use IP for repurposed drug (Dendocrin™) over a broad therapeutic range; leveraging 505(b)(2) regulatory pathway for known molecules.

Opportunities

Targeting a large and growing addressable market of 4-5 million Stage 3/4 CKD patients with SHPT in the US alone, where current treatments are suboptimal.

The 505(b)(2) pathway offers a faster, lower-cost route to market compared to traditional drug development, enhancing capital efficiency.

Risk Factors

High single-asset dependency on Dendocrin™.

Execution risk includes the need to successfully complete clinical trials and secure FDA approval despite using a known molecule.

The company is reliant on raising additional capital to fund operations through development.

Competitive Landscape

Competes against standard-of-care vitamin D analogues (e.g., paricalcitol, calcitriol) and nutritional vitamin D, which have limitations in efficacy and safety. May also face competition from other novel therapies in development for mineral bone disorder in CKD. Success hinges on demonstrating superior clinical profile.

More companies in Small Molecule Drugs →More companies in United States →